Basilea and J&J terminate Zeftera deal after CHMP negative opinion
This article was originally published in Scrip
Executive Summary
The EU's CHMP has refused to endorse the approval of Basilea Pharmaceutica's intravenous broad-spectrum cephalosporin antibiotic Zeftera (ceftobiprole) for the treatment of complicated skin and skin structure infections.